Latanoprost Zentiva (Latanoprost)

• Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure.
• Open-angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.
• Ocular hypertension: lowers pressure to prevent progression to glaucoma.
• Normal‑tension glaucoma: helps maintain target pressure and protect visual fields.

• Latanoprost acts as an agonist of prostaglandin F2α receptors in the ciliary body, enhancing uveoscleral outflow of aqueous humor. By increasing this unconventional drainage pathway, it effectively reduces intra‑ocular pressure, thereby mitigating the risk of optic nerve damage associated with glaucoma.

Latanoprost may cause ocular and systemic reactions. Patients should be aware of both common and rare events.

Common Side Effects

• Eye redness (hyperemia)
• Increased eyelash length and thickness
• Darkening of the iris (permanent pigment change)
• Eye irritation or foreign‑body sensation
• Blurred vision shortly after instillation
• Mild eye discomfort or itching

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, anaphylaxis)
• Uveitis or intra‑ocular inflammation
• Macular edema, especially in patients with risk factors
• Paradoxical increase in intra‑ocular pressure
• Corneal edema or endothelial changes
• Vision loss due to optic nerve compromise

• Before initiating therapy, clinicians should evaluate ocular health and monitor for changes during treatment.
• Assess baseline intra‑ocular pressure: ensure appropriate target pressure is set.
• Monitor iris color changes: inform patients that pigmentation may be permanent.
• Avoid use in active ocular inflammation: defer treatment until resolved.
• Exercise caution in patients with a history of herpetic eye disease: risk of reactivation.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, requiring attention to combined effects.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analog eye drops: may increase ocular irritation.
• Use with non‑steroidal anti‑inflammatory eye drops (e.g., ketorolac): may diminish latanoprost efficacy.
• Systemic carbonic anhydrase inhibitors combined with latanoprost: additive intra‑ocular pressure reduction, monitor closely.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: additive pressure‑lowering effect, watch for over‑reduction.
• Alpha‑agonist eye drops: potential synergistic IOP decrease.
• Systemic antihistamines: may exacerbate dry‑eye symptoms.